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Since Framingham Heart Study investigators first con-
firmed the existence and importance of cardiac risk factors
in 1961 (1), clinicians and scientists have been seeking to
refine our ability to predict cardiovascular disease risk.
These efforts stem from an appreciation that atherosclerosis
begins at a very young age but is clinically silent for many
years and also that during this latent period it is possible to
delay or prevent the onset of its devastating and systemic
clinical manifestations. Thus, efforts have focused on iden-
tifying risk factors, not for their own sake, but so that they
may be modified and, through this modification, reduce the
burden of disease. This trio—risk stratification, risk modi-
fication, and altered outcomes—is one of the foundations of
cardiovascular medicine and defines a preventive paradigm
of medical care that is increasingly receiving attention from
caregivers across many specialties, patients, and the public.
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At the present time, the state of the art in cardiovascular
risk assessment and modification is the National Choles-
terol Education Program Adult Treatment Panel III, a
National Institutes of Health–convened, consensus panel–
endorsed risk assessment tool based largely on age and
counting major risk factors to estimate 10-year coronary
heart disease (CHD) risk based on Framingham data. It is
easy to perform and scientifically well validated for the
middle-aged, Caucasian population from which it was
derived. However, it is not perfect, particularly in predicting
risk in other populations and in individuals. There are also
other reasons why we should seek to improve our ability to
estimate risk. In the Framingham risk score, the significance
of advancing age overwhelms most risk factors, making it
difficult to identify low-risk elderly individuals, even among
those without risk factors. The Framingham risk score also
fails to adjust for the severity of risk factors, their treatment,
other genetic factors, lifestyle, and interactions between risk
factors. Finally, because CHD is so common, many affected
individuals actually fall within the normal range of variables
such as cholesterol, making it even harder to predict
individual risk.
In this issue of the Journal, Tsang et al. (2) propose that
transthoracic echocardiography adds significantly to our
current ability to assess risk. Drawing on a moderately sized
(for epidemiologic studies) community-based population of
elderly patients undergoing clinically indicated echocardio-
grams, the authors compare a variety of clinical and echo-
cardiographic variables to the development of virtually any
form of cardiovascular disease. Of the clinical variables, age,
gender, diabetes, and high blood pressure predict outcomes,
whereas smoking, cholesterol levels, or a family history of
CHD does not. Although some of these findings are
expected, the lack of significance of some known risk factors
is of concern. Other limitations relate to the cohort studied,
particularly their homogeneity and that they were clinically
referred rather than being a community sample.
Of the echocardiographic variables examined, reduced
ejection fraction, left ventricular (LV) hypertrophy, and
diastolic dysfunction score were associated with poorer
outcomes, as has been noted by others. However, left atrial
(LA) volume (but not dimension) was also associated with
poorer outcomes. Because LA diameter would be expected
to track with LA volume, it is unclear why there should be
this disconnect. Nevertheless, the finding that LA size is
related to prognosis is new and of interest. Perhaps its
novelty is related to the fact that few evaluations of cardiac
risk in otherwise healthy individuals have considered de-
tailed echocardiographic findings as predictive variables.
Exceptions include the Framingham study, which pro-
nounced LV hypertrophy a risk factor 13 years ago (3) and,
along with the present authors, has noted a poorer outcome
in those with asymptomatic systolic and/or diastolic dys-
function (4). The Tsang et al. (2) data suggest that echo-
cardiography in general, and evaluation of LA size in
particular, should be included among tests and variables
offering insight into cardiovascular risk.
There is substantial biologic plausibility to the prognostic
significance of LA volume. The left atrium (LA) is most
commonly thought of as a transporting chamber, receiving
blood from the pulmonary veins and conveying it to the left
ventricle (LV) through both passive and active diastolic
filling. However, the LA also functions as a volume sensor
of the heart, releasing natriuretic peptides in response to
stretch and other neurohormones and generating a reflex
tachycardia in response to increased venous return (Bain-
bridge reflex). The LA also reflects LV filling pressure and
is capable of remodeling (enlarging) in response to its
elevation. It is in this final role, as an ongoing biomarker or
transducer of sustained elevations in LV filling pressures,
that LA size captures our attention.
A great deal of research has been conducted on nonin-
vasive assessments of diastolic function. Investigators and
clinicians alike have struggled with the load dependence of
easy-to-obtain measures, such as rapid filling rates and
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mitral E and A velocities, and with the technical difficulties
of obtaining pulmonary vein flows and assessing the angle of
the color M-mode LV inflow. At best, these techniques
present only a snapshot view of diastolic function—the
pattern would be altered if loading conditions changed.
Clinicians need a measure of diastolic dysfunction that is
easy to obtain, adequately reflects underlying abnormalities,
and has similar prognostic significance. The Tsang et al. (2)
data suggest that this elusive measure is LA volume.
Left atrial size is certainly easy to assess. With the advent
of hand-carried ultrasound, it can be a bedside or point of
care measure, possibly routinely obtainable as part of a
comprehensive physical examination. Even more important,
the Tsang et al. (2) data suggest that the hypothesis that LA
size represents the integration of LV diastolic performance
over time is clinically valid. Left atrial volume thereby
provides a long-term view of whether or not the patient has
the “disease” of diastolic dysfunction, regardless of whatever
loading conditions are present at the time of the examina-
tion. Drawing a parallel to two of the most commonly used
diagnostic tests in diabetes is nearly irresistible. Just as
serum glucose is used to assess transient diabetic control,
LV filling pressure is used to assess transient loading
conditions. In turn, the diastolic function corollary of
measurement of hemoglobin A1C (a long-term biomarker of
average metabolic state) is LA size (a long-term biomarker
of average LV diastolic pressure, and hence, when increased,
of diastolic dysfunction). The message is simple: in the
absence of other contributing pathology such as mitral valve
disease, if the LA is large, the patient has had a sustained
elevation in LV filling pressure, and hence has chronic
diastolic dysfunction.
The Tsang et al. (2) report is of interest in other ways as
well. Epidemiologic studies rarely include such large num-
bers of the elderly (average age 75 years), despite their
growing demographic importance. More interestingly, few
epidemiologic studies have considered and combined such a
broad range of cardiovascular outcomes—heart failure,
atrial fibrillation, myocardial infarction, surgical or percuta-
neous revascularization, stroke or transient ischemic at-
tack—in addition to death. This novel combined end point
allowed the authors to develop a single, unifying prediction
model, rather than separate models for each type of event.
This is arguably more clinically relevant than determining
risk for any single one of its component events. Interest-
ingly, in contrast to epidemiologic studies, randomized
clinical trials routinely utilize a combined end point
(MACE, or major adverse cardiovascular events), similar to
the present study’s. The Tsang et al. (2) approach is worth
keeping in mind for future studies.
Many studies evaluating cardiovascular risk place an
emphasis on the presence of clinical disease—diabetes,
hypertension, hyperlipidemia—and minimize subclinical or
mechanistic markers that may be more predictive. In this
sense, the prognostic value of high sensitivity C-reactive
protein is an important example, as it detects the inflam-
matory component of the disease process as it is occurring,
and not simply its end point. Other “non-traditional” tests
that detect the actual burden of subclinical disease are also of
value. The best studied of these, carotid intima medial
thickness, has been proven in multiple cohorts to prospec-
tively predict both heart attack and stroke (5). A $68 million
NIH-funded trial, the Multi-Ethnic Study of Atheroscle-
rosis (MESA), involving six centers and 6,500 participants
age 45 to 84 years, is examining the relative value of such
tests, including cardiac magnetic resonance imaging, carotid
intima medial thickness, ankle-brachial index, coronary
calcium scores, and inflammatory and genetic markers.
Echocardiography is not included in the trial, which could
have made it an excellent validation of the Tsang et al. (2)
data in a much larger population. Future studies will be
needed to determine the relative value of LA size in relation
to other noninvasive tests.
Tsang et al. (2) have taken the relationship between LA
size and diastolic dysfunction and analyzed its clinical
relevance. The association needs to be studied prospectively,
and the applicability of these data to clinical care remains to
be defined. Nevertheless, their findings suggest that echo-
cardiographically determined LA size may become an im-
portant clinical risk stratifier in pre-clinical cardiovascular
disease.
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